Theravance biopharma, inc. (TBPH)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue:
Revenue

87,938

73,414

59,652

60,063

57,389

60,370

49,148

40,585

20,618

15,386

16,563

31,363

33,325

48,648

46,849

38,472

40,135

42,126

39,666

35,304

31,144

11,688

10,430

4,118

1,149

226

0

0

0

Costs and expenses:
Cost of goods sold

-

-

-

-

-

715

3,199

3,479

6,291

6,030

4,060

3,407

2,681

2,894

4,948

5,197

5,064

4,657

4,679

4,467

4,241

4,058

836

467

188

0

0

0

0

Research and development

231,443

219,248

204,492

205,179

207,401

201,348

200,131

186,781

181,087

173,887

164,849

157,457

146,599

141,712

132,100

130,516

128,824

129,165

138,955

146,912

162,818

168,522

158,800

152,777

136,894

120,579

0

0

0

Selling, general and administrative

107,220

106,081

98,492

94,760

97,540

97,058

101,124

100,178

99,510

95,592

86,435

85,777

81,699

84,509

88,208

90,767

92,051

90,203

87,910

82,770

74,343

71,647

61,660

52,756

48,195

35,931

0

0

0

Total costs and expenses

338,663

325,329

303,616

301,276

304,830

299,121

304,454

290,438

286,888

275,509

255,344

246,641

230,979

229,115

225,256

226,480

225,939

224,025

231,544

234,149

241,402

244,227

221,296

206,000

185,277

156,510

0

0

0

Loss from operations

-250,725

-251,915

-243,964

-241,213

-247,441

-238,751

-255,306

-249,853

-266,270

-260,123

-238,781

-215,278

-197,654

-180,467

-178,407

-188,008

-185,804

-181,899

-191,878

-198,845

-210,258

-232,539

-207,864

-196,754

0

-

0

0

-

Income from investment in TRC, LLC

40,991

33,705

27,220

23,142

16,725

11,182

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

33,945

31,862

27,898

21,967

16,203

10,482

8,548

8,547

8,547

8,547

7,814

5,678

3,541

1,404

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other-than-temporary impairment loss

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income, net

7,060

8,395

15,080

14,367

13,277

11,966

5,354

5,102

5,243

4,789

4,053

3,273

2,156

1,312

950

710

606

631

1,502

2,066

2,076

1,865

882

214

0

-

0

0

-

Loss before income taxes

-252,083

-241,677

-229,562

-225,671

-233,642

-226,085

-252,576

-258,493

-276,718

-271,711

-250,542

-217,683

-199,039

-180,559

-177,457

-187,298

-185,198

-181,268

-190,376

-196,779

-208,182

-230,674

-206,982

-196,540

0

-

0

0

-

Provision for income tax expense

-5,180

-5,200

-8,566

-3,673

-10,664

-10,600

-310

1,217

8,461

13,700

15,273

15,217

14,799

10,110

-9,292

-5,781

-3,303

951

11,325

12,103

11,312

6,364

6,824

1,723

0

-

0

0

-

Net loss

-246,928

-236,455

-221,035

-222,037

-223,017

-215,524

-252,260

-259,704

-285,173

-285,405

-265,815

-232,900

-213,838

-190,669

-168,165

-181,517

-181,895

-182,219

-201,701

-208,882

-219,494

-237,038

-216,808

-203,391

-184,128

-156,284

0

0

0

Net unrealized gain on available-for-sale investments

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-

Total comprehensive loss

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

-

-

-

-

-

0

Net loss per share:
Basic and diluted net loss per share (in dollars per share)

-1.40

-1.16

-1.05

-0.72

-1.32

-0.91

-1.10

-0.76

-1.22

-1.64

-1.27

-1.27

-1.27

-1.37

-0.73

-1.06

-1.10

-1.23

-1.40

-1.42

-1.29

-2.02

-1.72

-1.83

-1.89

-

-1.29

-1.23

-

Shares used to compute basic and diluted net loss per share (in shares)

59,463

56,115

55,858

55,529

54,938

54,573

54,248

53,799

53,256

52,925

52,611

52,255

51,617

49,641

46,470

44,407

38,326

36,549

33,689

33,532

32,830

31,757

31,754

31,768

31,741

-

31,741

31,768

-

Share-based compensation expense

63,506

60,450

48,251

46,978

49,535

51,313

57,392

56,331

52,874

49,145

41,392

40,602

40,108

41,169

42,640

44,996

49,754

54,050

51,889

0

0

-

0

-

-

-

-

-

-

Product sales
Revenue

-

-

-

-

-

15,304

17,013

17,304

15,417

14,788

15,696

15,457

17,342

17,603

16,263

14,674

11,439

9,408

7,025

6,016

4,753

4,418

3,109

1,806

945

0

0

0

0

Collaborative revenue
Revenue

32,544

31,250

31,871

32,024

42,489

41,791

32,135

23,281

5,201

598

867

15,906

15,983

31,045

30,586

23,798

28,696

32,718

32,641

29,288

26,391

7,270

7,321

2,312

204

226

0

0

0

Licensing revenue
Revenue

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Mylan collaboration agreement
Revenue

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development
Share-based compensation expense

30,659

28,953

24,143

23,979

25,163

25,563

27,425

26,136

24,149

22,691

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative
Share-based compensation expense

32,847

31,497

24,108

22,999

24,372

25,750

29,967

30,195

28,725

26,454

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-